Abstract
In recent years, the use of haploidentical donors for hematopoietic cell transplantation has expanded rapidly. Approximately 50% of patients requiring hematopoietic cell transplant lack a traditional donor. The use of HLA haploidentical-related donors is attractive due to nearly universal availability of this graft source. We summarize the current and future need for haploidentical donors and detail the rise of post-transplant cyclophosphamide as the dominant haploidentical approach. Further, we examine ongoing controversies in the field of haploidentical transplant, including conditioning regimens and graft source. Finally, we review the evidence available from preliminary comparative studies and discuss future direction of research.
Similar content being viewed by others
References
Beatty PG, Dahlberg S, Mickelson EM, Nisperos B, Opelz G, Martin PJ et al. Probability of finding HLA-matched unrelated marrow donors. Transplantation 1988; 45: 714–718.
Besse K, Maiers M, Confer D, Albrecht M . On modeling human leukocyte antigen–identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source. Biol Blood Marrow Transplant 2015; 22: 1–8.
Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Matthews TJ . Births: final data for 2013. Natl Vital Stat Rep 2015; 64: 1–65.
van Agthoven M, Groot MT, Verdonck LF, Löwenberg B, Schattenberg AVMB, Oudshoorn M et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002; 30: 243–251.
Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014; 371: 339–348.
Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V et al. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant 2012; 48: 346–350.
Morishima Y, Kashiwase K, Matsuo K, Azuma F, Morishima S, Onizuka M et al. Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood 2015; 125: 1189–1198.
Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576–4583.
Fuchs EJ . Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program 2012; 2012: 230–236.
Bashey A, Solomon SR . T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant 2014; 49: 999–1008.
Fuchs EJ . Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts. Curr Opin Hematol 2012; 19: 440–447.
Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983; 1: 612–615.
Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765–771.
Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990; 29: 79–91.
Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767–1777.
Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C et al. Successful engraftment of T-cell-depleted haploidentical ‘three-loci’ incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948–3955.
Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.
Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.
Berenbaum MC, Brown IN . Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 1963; 200: 84.
Colson YL, Wren SM, Schuchert MJ, Patrene KD, Johnson PC, Boggs SS et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol 1995; 155: 4179–4188.
Colson YL, Li H, Boggs SS, Patrene KD, Johnson PC, Ildstad ST . Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 1996; 157: 2820–2829.
Owens AHJ, Santos GW . The effect of cytotoxic drugs on graft-versus-host disease in mice. Transplantation 1971; 11: 378–382.
Robinson TM, O’Donnell PV, Fuchs EJ, Luznik L . Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 2016; 53: 90–97.
Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013; 5: 211ra157.
O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377–386.
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.
Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1835–1844.
Luger SM, Ringdén O, Zhang M-J, Pérez WS, Bishop MR, Bornhauser M et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203–211.
Solomon SR, Sizemore Ca, Sanacore M, Zhang X, Brown S, Holland HK et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival. Biol Blood Marrow Transplant 2012; 18: 1859–1866.
Solomon SR, Sizemore Ca, Sanacore M, Zhang X, Brown S, Holland HK et al. Total body irradiation–based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant 2015; 21: 1299–1307.
Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117–122.
Symons HJ, Chen A, Gamper C, Cooke KR, Showel M, Bolaños-Meade J et al. Haploidentical BMT using fully myeloablative conditioning, T cell replete bone marrow grafts, and post-transplant cyclophosphamide (PT/CY) has limited toxicity and promising efficacy in largest reported experience with high risk hematologic malignancies. Biol Blood Marrow Transplant 2015; 21: S29.
Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121: 849–857.
Solomon SR, Solh M, Morris LE, Holland HK, Bashey A . Myeloablative conditioning with PBSC grafts for T cell-replete haploidentical donor transplantation using posttransplant cyclophosphamide. Adv Hematol 2016; 2016: 1–7.
Pingali SR, Milton D, Di Stasi A, Patel RD, Kebriaei P, Popat UR et al. Haploidentical transplantation for advanced hematologic malignancies using melphalan-based conditioning-mature results from a single center. Biol Blood Marrow Transplant 2014; 20: S40–S41.
HRSA. Donor Registry Transplant Data. Available at: http://bloodcell.transplant.hrsa.gov/research/transplant_Data/registry_TX_data/index.html. Accessed on 2 April 2016.
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487–1496.
Sengsayadeth S, Savani BN, Blaise D, Mohty M . Haploidentical transplantation: selecting optimal conditioning regimen and stem cell source. Semin Hematol 2016; 53: 111–114.
Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231–1237.
Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.
Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the soeiete francaise de greffe de moelle. J Clin Oncol 2000; 18: 537–546.
Mielcarek M, Storer B, Martin PJ, Forman SJ, Negrin RS, Flowers ME et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood 2012; 119: 2675–2678.
Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.
Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685–3691.
Schmitz N, Eapen M, Horowitz MM, Zhang M-J, Klein JP, Rizzo JD et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 4288–4290.
Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010; 11: 331–338.
Ciurea SO, Zhang M-J, Bacigalupo Aa, Bashey A, Appelbaum FR, Aljitawi OS et al. Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. Blood 2015; 126: 1033–1040.
Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20: 890–895.
Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after Busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant 2015; 21: 1646–1652.
Bhamidipati PK, DiPersio JF, Stokerl-Goldstein K, Rashidi A, Gao F, Uy GL et al. Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplant 2014; 49: 1124–1126.
Grosso D, Carabasi M, Filicko-O’Hara J, Kasner M, Wagner JL, Colombe B et al. A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood 2011; 118: 4732–4739.
Grosso D, Gaballa S, Alpdogan O, Carabasi M, Filicko-O’Hara J, Kasner M et al. A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease. Biol Blood Marrow Transplant 2015; 21: 646–652.
Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014; 20: 724–729.
Kekre N, Antin JH . Cord blood versus haploidentical stem cell transplantation for hematological malignancies. Semin Hematol 2016; 53: 98–102.
Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118: 282–288.
Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014; 20: 1573–1579.
Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia 2015; 29: 1891–1900.
Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen–matched unrelated and related donors. Biol Blood Marrow Transplant 2014; 20: 1975–1981.
Gaballa S, Palmisiano N, Alpdogan O, Carabasi M, Filicko-O’Hara J, Kasner M et al. A two-step haploidentical versus a two-step matched related allogeneic myeloablative peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2016; 22: 141–148.
Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 31: 1310–1316.
Burroughs LM, O’Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1279–1287.
Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donors. Blood 2015; 127: 938–947.
Chang Y-J, Huang X-J . Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience. Semin Hematol 2016; 53: 82–89.
Huang X-J, Liu D-H, Liu K-Y, Xu L-P, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291–297.
Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 2014; 124: 843–850.
Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015; 125: 3956–3962.
Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MTL et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2014; 29: 1–10.
Shin SH, Kim JH, Jeon YW, Yoon JH, Yahng SA, Lee SE et al. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome. Biol Blood Marrow Transplant 2015; 21: 342–349.
Perruccio K, Topini F, Tosti A, Carotti A, Aloisi T, Aversa F et al. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis 2008; 40: 76–83.
Bastien JP, Krosl G, Therien C, Rashkovan M, Scotto C, Cohen S et al. Photodepletion differentially affects CD4+ Tregs versus CD4+effector T cells from patients with chronic graft-versus-host disease. Blood 2010; 116: 4859–4869.
Perruccio K, Topini F, Tosti A, Carotti A, Burchielli E, Ruggeri L et al. Optimizing a photoallodepletion protocol for adoptive immunotherapy after haploidentical SCT. Bone Marrow Transplant 2012; 47: 1196–1200.
Roy D, Lachance S, Kiss T, Cohen S, Busque L, Fish D et al. Haploidentical stem cell transplantation: High doses of alloreactive-T cell depleted donor lymphocytes administered post-transplant decrease infections and improve survival without causing severe Gvhd. Blood 2009; 114: 512.
Roy D, Maertens J, IWalker I, Lachance S, Roy J, Foley S et al. Selective photodepletion of recipient-alloreactive T-cells enables safe and efficacious haploidentical HSCT: initial results from a phase 2 trial in patients with AML, ALL, and MDS. Blood 2014; 124: 314.
Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 2013; 15: 1253–1258.
Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C et al. Gammadelta T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-alphabeta+/CD19+ lymphocytes. Blood 2015; 125: 2349–2358.
Lang P, Feuchtinger T, Teltschik H-M, Schwinger W, Schlegel P, Pfeiffer M et al. Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant 2015; 50: S6–S10.
McCurdy SR, Kanakry JA, Showel MM, Tsai H-L, Bolaños-Meade J, Rosner GL et al. Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015; 125: 3024–3031.
Blaise D, Fürst S, Crocchiolo R, El-Cheikh J, Granata A, Harbi S et al. Haploidentical T cell–replete transplantation with post-transplantation cyclophosphamide for patients in or above the sixth decade of age compared with allogeneic hematopoietic stem cell transplantation from an human leukocyte antigen–matched related or unrelated donor. Biol Blood Marrow Transplant 2016; 22: 119–124.
Kasamon YL, Bolanos-Meade J, Prince GT, Tsai H-L, McCurdy SR, Kanakry JA et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol 2015; 33: 3152–3161.
Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012; 120: 4285–4291.
Slade M, Goldsmith SR, Romee R, DiPersio JF, Dubberke E, Westervelt P et al. Infectious complications after peripheral blood (PB) haploidentical hematopoietic cell transplantation (haplo-HCT). Biol Blood Marrow Transplant 2016; 22: S176–S177.
Crocchiolo R, Bramanti S, Vai A, Sarina B, Mineri R, Casari E et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis 2015; 17: 242–249.
Goldsmith SR, Slade M, Lawrence SJ, DiPersio JF, Westervelt P, Uy GL et al. Cytomegalovirus viremia and relapse after haploidentical hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016; 22: S320.
Ramlal R, Sasaki K, Cerrada SL, Srour SA, Chen J, Rondon RG et al. Viral reactivation in haploidentical transplants using post-transplantation cyclophosphamide - a single institution experience. Biol Blood Marrow Transplant 2016; 22: S375–S376.
Roberto A, Castagna L, Zanon V, Bramanti S, Crocchiolo R, McLaren JE et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood 2015; 125: 2855–2865.
Cieri N, Oliveira G, Greco R, Forcato M, Taccioli C, Cianciotti B et al. Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood 2015; 125: 2865–2874.
Pérez-Corral AM, Champ D, Anguita J, Pascual C, Gayoso J, Bastos-Oreiro M et al. Delayed reconstitution and immature phenotype of natural killer(NK) cells following postransplant cyclophospamide in 30 unmanipulated haploidentical transplantation patients. A prospective analysis. Haematologica 2015; 100: 610–611.
Jaiswal S, Chakrabarti A, Chatterjee S, Ray K, O’Donnell P, Chakrabarti S . Early donor lymphocyte infusion and NK ligand mismatched donor might improve the outcome of relapsed/refractory acute myeloid leukemia following posttransplantation cyclophosphamide-based haploidentical pbsc transplantation with myeloablative conditioning. Biol Blood Marrow Transplant 2016; 22: S81–S82.
Ciurea SO, Lee DA, Cao K, Rondon G, Chen J, Willis DB et al. Phase I trial of IL-21 ex vivo expanded NK cells administration to prevent disease relapse after haploidentical stem-cell transplantation for myeloid leukemias. Blood 2015; 126: 102.
Thakar M, Hari PN, Keever-Taylor CA, Jones L, Heimfeld S, Sandmaier BM . Donor natural killer (NK) cell immunotherapy following non-myeloablative HLA-haploidentical hematopoietic cell transplantation (HCT) improves relapse and progression free survival (PFS) in patients with hematologic malignancies. Biol Blood Marrow Transplant 2016; 22: S43–S44.
Ovechkina V, Bondarenko S, Morozova E, Slesarchuk O, Stancheva N, Ivanova N et al. Efficiency of hypomethylating agents after allogenic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2015; 50: S484.
Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 2016; 173: 444–455.
Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI et al. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus and mycophenolate mofetil. Biol Blood Marrow Transplant 2016; 22: 1037–1042.
Acknowledgements
Research reported in this publication was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1TR000448, sub-award TL1TR000449, from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Slade, M., Fakhri, B., Savani, B. et al. Halfway there: the past, present and future of haploidentical transplantation. Bone Marrow Transplant 52, 1–6 (2017). https://doi.org/10.1038/bmt.2016.190
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.190
- Springer Nature Limited
This article is cited by
-
Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm
Bone Marrow Transplantation (2023)
-
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine)
Annals of Hematology (2020)
-
Haploidentical hematopoietic bone marrow transplantation followed by living kidney transplantation from the same donor in a sickle cell disease patient with end-stage renal failure
Annals of Hematology (2017)